AI assistant
Vaxcyte, Inc. — Director's Dealing 2020
Jun 12, 2020
31100_dirs_2020-06-11_0bc786c0-90c6-4091-928a-7f9337476beb.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Vaxcyte, Inc. (PCVX)
CIK: 0001649094
Period of Report: 2020-06-11
Reporting Person: Abingworth LLP (10% Owner)
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Series A Preferred Stock | $0.00 | Common Stock, $0.001 par value per share (2185415) | Indirect | ||
| Series B Preferred Stock | $0.00 | Common Stock, $0.001 par value per share (1217074) | Indirect | ||
| Series C Preferred Stock | $0.00 | Common Stock, $0.001 par value per share (454812) | Indirect | ||
| Series D Preferred Stock | $0.00 | Common Stock, $0.001 par value per share (298917) | Indirect |
Footnotes
F1: The shares are held by Abingworth Bioventures VI LP ("Abingworth VI"). Abingworth Bioventures VI GP LP ("Abingworth GP") serves as the general partner of Abingworth VI. Abingworth General Partner VI LLP, serves as the general partner of Abingworth GP. Abingworth VI (acting by its general partner Abingworth GP, acting by its general partner Abingworth General Partner VI LLP) has delegated to Abingworth LLP ("ALLP"), all investment and dispositive power over the securities held by Abingworth VI. ALLP holds the reported securities indirectly through Abingworth VI. ALLP disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein. This report shall not be deemed an admission that the reporting person, Abingworth VI or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
F2: Each share of Series A, Series B, Series C and Series D Preferred Stock is convertible into Common Stock, $0.001 par value per share ("Common Stock") on a 1:1 basis and has no expiration date. Immediately prior to the consummation of the Issuer's initial public offering, all shares of Series A, Series B, Series C and Series D Preferred Stock will be converted into shares of Common Stock for no consideration.